CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 342 enrolled
Drug / intervention
tadalafil +1 moredrug
Likely dose
tadalafil 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00422734
NCT00422734Phase 3Completed

Tadalafil 5 mg Once a Day Compared to Placebo in Improving Erectile Dysfunction and Sexual Quality of Life

Eli Lilly and Company·interventional·Posted Jan 17, 2007·Updated Jun 10, 2009

In Brief

A Phase 3 clinical trial evaluating tadalafil and Placebo for Impotence. Completed, enrolled 342 participants across 19 sites in 5 countries.

Detailed Summary

To determine if tadalafil 5 mg daily compared to placebo when given for 12 weeks improves getting and maintaining an erection in men with erectile dysfunction and if there are improvements in the sexual quality of life of the man and his female study partner

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImpotence
CountriesAustria, France, Germany, Mexico, United States
CollaboratorsICOS Corporation

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 17, 2007
Enrollment StartNov 1, 2006
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.5 years ago

Interventions

tadalafildrug

5 mg tadalafil tablet taken by mouth once a day for 12 weeks

Placebodrug

placebo tablet taken by mouth once a day for 12 weeks